ReBio

2 known investors

ReBio develops targeted, locally delivered therapies for ocular oncology, using its proprietary SiSu conjugate platform to program drug exposure for eye diseases. Its lead program, RBP-01, is a SiSu-conjugated PKC inhibitor for uveal melanoma delivered via intravitreal injection, with additional programs targeting retinoblastoma, glaucoma, and post-op ocular inflammation.